CMS, BIO spin Part B data in opposite directions

CMS and the biopharma industry are presenting conflicting explanations for a spike in Medicare Part B premiums and deductibles.

CMS says the increases are “largely due to rising spending on physician-administered drugs” (see “Medicare Part B Premium Spike Could Create Pressure for International Reference Pricing.”).

BIO is

Read the full 474 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE